Vertex Pharmaceuticals has analysts doing financial backflips as they boost its price targets, with Royal Bank of Canada ...
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback